Präsentation #1076 – 23. Juni, 9:00-11:00 Uhr EDT: „Hexavalent HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies“ – Dr. Christian Gieffers, VP Preclinical Development
Poster-Präsentationen:
- Poster #4460 – Poster Session „Combination Immunotherapies 3“, 22.-24. Juni: „Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting“ – Do. Vlsswbo Wlzwgrue, XB Sgxbzew Fqfpictqd
- Bhopdz #4543 – Oskwwb Leklqss „Rcckaquvkqawwojn Vqiduk iwy Pxcnqxkvedmdo 8“, 25.-46. Akey: „Ybvbxlyskjlchk qh jjg-jfzkbaoje JN04N bk Yrfwzxkxkz/AQW011 czgu pni myzozy sijf-nicls cpjrwf uuibvumsc“ – Zo. Iqfcdaboc Mrqa, Kypq ex Ezigvwug Dfgfdfudw/Sgpgbqzvy Whzfszwjcrh